cyrilzakka/clinical-trials huggingface dataset:
Decoding Risks and Rewards in Ischemic Stroke Surgery

In the high-stakes battle against ischemic cerebrovascular disease, where every second counts and the margin for error is slim, how do the investigators tip the scales in favor of patient survival and improved outcomes? This groundbreaking study, the first nationwide, population-based analysis with long-term follow-up in an Asian context, dives deep into this critical question. Leveraging an expansive dataset from Taiwan's National Health Insurance Research Database, the investigators scrutinize the efficacy and risks of aggressive surgical interventions-specifically, EC-IC bypass, CEA, and CAS-in a cohort of over 84,000 patients.

This paper serves as a milestone, bridging the gap between medical idealism and clinical reality. It calls for a surgical renaissance, emphasizing the need for refining techniques and enhancing patient selection protocols. If participants're looking for a comprehensive, nuanced, and, above all, actionable insight into the surgical treatment of ischemic cerebrovascular disease, this is the study that could redefine the paradigm.


Eligibility Criteria:
Inclusion Criteria:

- All participants underwent either a computed tomography (CT) scan or magnetic resonance imaging (MRI) within two days before or after hospital admission.

The date of the first ischemic stroke hospitalization served as the index event.

Among these patients, those who underwent surgical interventions post-hospitalization were categorized into three distinct groups: CEA (ICD-9-CM code 3812), CAS (ICD-9-CM code 3990), and EC-IC (ICD-9-CM code 3928), with the operation date being the index date.

Those who did not receive any surgical interventions were considered the non-intervention control group and had their first hospitalization date as the index date.

Exclusion Criteria:

- patients with a history of: any stroke subtype (ICD-9-CM codes 430-434), Moyamoya disease (ICD-9-CM code 437.5), cancer (ICD-9-CM codes 140-239), trauma (various ICD-9-CM codes), transient ischemic attack (ICD-9-CM code 435), unruptured cerebral aneurysm (ICD-9-CM code 437.3), or subarachnoid hemorrhage (ICD-9-CM code 430).
Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations

The goal of this study is to find the best ways to increase colorectal cancer (CRC) screening.

Colorectal Cancer is preventable and curable but is still the second most common cause of cancer death in the U.S. Minorities and those with low income have more CRC than middle and high income Whites.. They also get fewer CRC screening tests. Low knowledge of CRC screening may, in part, drive this lower test use. We need new ways to improve CRC screening in primary care clinics where many minority and uninsured patients receive health care.

Eligibility Criteria:
Inclusion Criteria:

* Have a home address and access to a working telephone
* Pass Mini-Cog assessment

Exclusion Criteria:

* FIT (fecal immunochemical test) test within 1 year, Sigmoidoscopy or Barium enema within 5 years, or Colonoscopy within 10 years
* Acute medical illness,
* current GI bleed
* history of adenomatous polyps
* Colorectal Cancer
* 1st degree relative with CRC \< age 60 years
* inherited polyposis/non-polyposis syndrome
* inflammatory bowel disease
* Another household member enrolled in the study
Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes

A total of 74 Adult Patients with type 2 diabetes mellitus (T2D) will be enrolled and randomized into 2 groups. The intervention group will receive oral magnesium (Mg) supplementation. The study objectives are:

1. To estimate level of Mg (total and ionized) in patient with type 2 DM.
2. To determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation.
3. To assess the correlation between serum Mg level and glycemic control and level of inflammatory mediators (CRP)

A total of 74 Adult Patients of both genders who had been diagnosed with T2D and are on oral anti-hyperglycemic drug and their HbA1C between 7and 8 %, will be enrolled in the study. Initially the study protocol will be explained \& informed written consent will be obtained from all participants. All subjects will be evaluated to ensure that they meet the eligibility criteria through: Full history taking, complete physical examination and investigations. the intervention group will receive oral magnesium (Mg) supplementation for 3 months (250 mg of elemental magnesium daily). The primary outcome is to determine the effect of Mg supplementation for diabetic patient on serum Mg level, glycemic control and level of inflammation.

Eligibility Criteria:
Inclusion Criteria:

* Patients with type 2 diabetes with HbA1C between 7 and 8%.
* Both genders will be included in this study.

Exclusion Criteria:

* Patients on insulin.

  * Patients on diuretics or angiotensin-converting enzyme inhibitors in the last 2 weeks.
  * Patients taking Mg containing supplements within 3 months.
  * Patients with significant gastrointestinal disorders (eg, chronic diarrhea).
  * Patients with impaired renal functions (eGFR\< 60 mL/min).
  * Heart block or heart failure
  * Patients treated with aldosterone antagonists.
  * Pregnant patients
  * Patients with evidence of infection.
  * Patients with chronic inflammatory conditions eg, SLE
Association Between Neuromuscular Parameters and Functional Assessment After ACL Reconstruction

The anterior cruciate ligament (ACL) injury is common in athletes aged 18 to 35. ACL reconstruction (ACLR) aims to restore knee stability in the process of returning to sports. Post-surgical rehabilitation focuses on optimizing biomechanical parameters, with neuromuscular and functional tests assessing muscle strength, proprioception, and dynamic stability. Isokinetic allows the measurement of muscle strength symmetry and proprioception, while the single-leg hop and landing tasks assess functional stability and are predictive of sports resumption and injury prevention. Despite progress, concerns remain about neuromuscular factors impacting knee stability, especially during landings, which can increase the risk of secondary ACL injuries.

This study proposes examining knee strength and proprioception using isokinetic dynamometry, alongside biomechanical assessments from functional tests, to explore their relationship to biomechanical features during landings, at 6-to-12 months post-ACL reconstruction. The hypothesis is that better muscle strength and proprioception correlate with improved knee control during landing tasks.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, aged 18-40, who have undergone a first ACL reconstruction more than 6 months ago and are being followed in a sports medicine care pathway
* Affiliated with a health insurance plan
* Information form: Non-objection to the use of data for research purposes

Exclusion Criteria:

* Previous ligament surgery of the lower limbs prior to ACL reconstruction
* Complex ligament injury (lateral ligaments, posterior cruciate ligament)
* Recent muscle injuries
* History of injury to the uninjured knee
* Pregnant woman
* Neurological history with residual effects or taking medication that affects balance/coordination
* Inability to perform a muscular assessment
* Postoperative complications (deep vein thrombosis, sepsis, stiffness/arthrofibrosis)
Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation

Pulmonary hypertension (PH) can be the result of various clinical conditions. It may be idiopathic or associated with various cardiovascular and lung disorders. Currently there is no test that can non-invasively detect abnormalities of the pulmonary circulation. There is a growing need for a non-invasive method to detect PH. There currently exists only ne agent approved in Canada for clinical imaging of the pulmonary circulation, 99mTc-labeled macroaggregates. This agent is exclusively used for the diagnosis of physical defects of the circulation due to pulmonary embolus. This agent is larger than small pulmonary vessels, limiting its sensitivity to detect small vascular defects, as well as potential infectious risks since albumin macroaggregates are derived from human albumin. There is need then for new lung tracers that could provide a greater safety profile while enabling functional as well as anatomical imaging of the pulmonary circulation. DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Hence the development of this novel AM derivative, PulmoBind, for molecular imaging of the pulmonary circulation. PulmoBind is labeled with 99mTc, the most commonly used imaging isotope in nuclear medicine.


Eligibility Criteria:
Inclusion Criteria:

* male or female greater than 18 years of age. Female subjects must be post-menopausal (defined as two years after menstrual cycle)
* within normal range for the following: BP systolic 100-140 mmHg and diastolic 50-90 mmHg;
* HR 60-100 beats per minute;
* oral temperature less than 37.6 degrees Centigrade;
* respiratory rate 12-20 breaths per minute;
* normal lung function tests;
* normal echocardiogram including estimation of pulmonary artery systolic pressure;
* normal chest x-ray; Normal electrocardiogram

Exclusion Criteria:

* any known chronic or acute medical condition with or without the need for chronic pharmacologic therapy or any condition that may interfere with normal biodistribution of DFH-12. Includes but not limited to:

  * lung parenchymal or lung vascular diseases such as chronic obstructive pulmonary disease,
  * bronchitis,
  * lung cancer,
  * pleural effusion,
  * emphysema,
  * asthma,
  * pulmonary fibrosis,
  * occupational lung disease,
  * pulmonary hypertension (primary or secondary),
  * systemic hypertension,
  * diabetes,
  * cancer,
  * kidney disease,
  * liver disease,
  * heart failure or previous myocardial infarction,
  * coronary artery disease,
  * peripheral vascular disease or inflammatory disease;
* subjects requiring chronic administration of any substance for a medical condition, active smoking or history of smoking for more than one year in the past 10 years, known self-reported alcoholism (active or abstinent);
* unable to tolerate study procedures ex.(venipuncture, movement restrictions during imaging);
* previous nuclear study since one week (to avoid cross-contamination)
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. Participants with overweight or obesity defined as at least one overweight/obesity indication of a specified body mass index (BMI) above or equal to (≥) 27.0 kilogram per meter square (kg/m\^2) and undefined obesity/overweight indications, defined by diagnoses and laboratory values
2. Participants with established ASCVD defined as a diagnosis of MI, diagnosis of ischemic stroke, and/or evidence of peripheral arterial disease
3. Participants who are above or equal to (≥) 45 years old by the end of data availability
4. Participants who initiated semaglutide 2.4 mg on or after the eligibility date and June4, 2021 (semaglutide 2.4 mg users) or participants with no evidence of semaglutide 2.4 mg usage (non-users) during January 1, 2016 to December 31, 2023
5. Participant with continuous insurance enrolment eligibility above or equal to (≥)12 months prior to the index date
6. Participants with re-confirmed overweight/obesity indication during the baseline period

Exclusion criteria:

1. Participants with a diagnosis of chronic or acute pancreatitis
2. Participants with a diagnosis of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
3. Participants with end-stage kidney disease (ESKD) including chronic or intermittent hemodialysis or peritoneal dialysis, kidney transplant, and/or record of estimate glomerular filtration rate less than (\<) 15 milliliter per minute per 1.73\*meter square (mL/min/1.73m\^2)
4. Pregnancy in female participants
5. Participants with evidence of diabetes including more or equal to (≥)2 diagnoses of type 1 diabetes or more or equal to ( ≥) 2 diagnoses of type 2 diabetes on distinct dates, use of a glucose-lowering agent, and/or glycated hemoglobin (HbA1c) laboratory result above or equal to 6.5 percent (%)
6. Use of a glucagon-like peptide-1 (GLP-1) or GLP-1/gastric inhibitory polypeptide (GIP) receptor ago-nist approved for weight management (excluding semaglutide 2.4 mg)
7. Participants with evidence of bariatric surgery
Sunfiber and the Microbiota

The aim of this study is to look at the effect Sunfiber has on the gut microbiota.

This is a randomized, double-blind, placebo-controlled crossover study with a 2 week washout period. Healthy volunteers will receive placebo, 4 grams, or 8 grams of Sunfiber in addition to their regular diet. Fecal samples will be collected for measurement of bowl function, including the gut microbiota.

Eligibility Criteria:
Inclusion Criteria

* Healthy male or female between the ages of 20-49 years
* Subject has a body mass index of ≥18.5 and ≤30 kg/m2 at screening visit.
* Subject is willing to stick to their normal habitual diet excluding the consumption of any unusual high energy-rich or fat-rich meals or prolonged fasting, etc. through the study period.
* Subject is willing to maintain their habitual physical activity patterns throughout the study period.
* Subject has been weight stable within the last 6 months.
* Subject has no health conditions that would prevent him or her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results.
* Low fiber consumer (≤14 g per day)
* Subject is willing to follow study procedures and dietary restrictions (ex: stick to habitual diet, refrain from consuming alcohol 24 hours prior to test days).
* Subject understands study procedures and signs forms providing informed consent to participate in the study.

Exclusion Criteria:

* History of a gastrointestinal disorder
* Lactose intolerant
* High fiber consumer (≥15 g per day)
* Use of pre-and probiotics in the past 90 days
* High protein consumer (i.e. vegetarians or those who follow diets high in protein such as paleo)
* History of psychological illness or conditions that may interfere with subjects ability to understand study directions
* Use of antibiotics or signs of active systemic infection in the last 6 months. Subjects who are on hypo/hypercaloric diet aiming for weight loss or weight gain
* History or presence of cancer in the prior 2 years (except for non-melanoma skin cancer).

Currently pregnant, lactating or planning to be pregnant during the study period

* Regular use of dietary supplements (ex: fish oil, riboflavin, etc.), 90 days prior to study inclusion
* Exposure to any non-registered drug product within the last 30 days prior to screening visit
* History of or strong potential for alcohol or substance abuse (within 12 months of screening visit). Alcohol abuse is defined as \>60g (men)/40g (women) pure alcohol per day (1.5 L/ 1 l beer resp. 0.75l/0.5l wine).
The VENTOR Clinical Study

To evaluate the initial safety and effectiveness of the Ventor Airway System in providing short-term ventilation support in non-breathing subjects during cardiopulmonary resuscitation (CPR) and respiratory arrests.


Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 18-75 years, inclusive
2. IHCA (non-traumatic)
3. At least 4 feet in height

Exclusion Criteria:

1. Intubated with an endotracheal tube (ET)
2. Valid do-not-attempt-resuscitation (DNAR) or study opt-out bracelet (including previous enrollment bracelet)
3. LAR or Family member objects to enrollment
4. Obvious signs of irreversible death (rigor mortis, dependent lividity, decapitation, transection, decomposition)
5. Responsive with an intact gag reflex
6. Blunt, penetrating, or burn-related injury, drowning, or electrocution
7. Known upper airway foreign body or mass
8. Lower airway obstruction
9. Dental gap of \< 2 cm
10. Ingested caustic substances
11. Medicine Admitting Note's medical history is incomplete or has only been completed by an emergency physician.
12. Known esophageal disease or facial/perforating neck trauma defined as study candidates with the following medical history:

    1. Diseases: (Esophageal Varices, Esophageal Cancer, Esophageal Strictures)
    2. Any patient on the following medications will be excluded: (Oxaliplatin, Leucovorin, Fluorouracil)
    3. Any patient with the following examination findings will be excluded: (Caput medusae, History or evidence of vomiting blood)
13. Known vulnerable subject other Inclusion #3, such as known (e.g.: prisoner, pregnancy, terminal illness, dementia)
14. History of medical, surgical or other conditions that, in the opinion of the investigator, would limit study participation
Effect of Pilates Exercises on Diastasis Recti Abdominis in Postpartum Women

The purpose of the study was to investigate the effect of Pilates exercises on diastasis recti abdominis in postpartum women.

Rectus diastasis is relatively common having negative health consequences for women during and after pregnancy (ante-and postnatal periods). Varying estimates of incidence of rectus diastasis have been reported ranging from 66% to 100% during the third trimester of pregnancy, and up to 53% immediately after delivery. Among patients with urogynecological disorders, 52% were found to have a rectus diastasis and 66% had at least one type of pelvic floor dysfunction.

A diastasis can contribute to lower back pain and strain due to other muscles being overworked or compensating for the lack of integrity of abdominals, unstable core, pelvic and back muscles, poor posture, shallow breathing and uterine prolapse. This may result in altered trunk mechanics, impaired pelvic stability and changed posture, which leave the lumbar spine and pelvis more vulnerable to injury.

Facilitation, concentric activation, and stabilization of the abdominal muscles occurred during core stability exercise are used to correct diastasis recti. Pilates has been known to improve the strength and flexibility of muscles, particularly the abdominal muscles, lower back, hip and buttocks i.e. the core musculature thus helping in improving core stability.

Uptill now, there was no previous studies have examined the impact of Pilates training on rectus abdominis diastasis in postpartum women. So, this study will be valuable benefits for medical services organizations and will increase body of knowledge of physical therapists in scientific field.

Eligibility Criteria:
Inclusion Criteria:

1. Postpartum women (7 days after delivery) having diastasis recti (separation between the two recti more than 2.5cm at the level of umbilicus).
2. Multiparous women (2-3) times delivered vaginally with or without episiotomy.
3. Their age ranged from 20 -35 years old.
4. Their BMI was less than 30 kg/cm2.

Exclusion Criteria:

1. Abdominal or back surgery.
2. Abdominal hernia.
3. History of abnormal pregnancy, uterine fibroid or polyhydraminos during pregnancy.
4. Neurological disorders as multiple sclerosis, stroke and spinal lesion.
5. Musculoskeletal diseases such as fractures muscle strains, severe knee osteoarthritis which may affect their physical activity.
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.


Eligibility Criteria:
Inclusion Criteria:

* Taiwanese male subjects between 50 and 80 years of age who had: a primary diagnosis of BPH, defined as having an enlarged prostate (confirmed by digital rectal examination \[DRE\] and/or B-mode ultrasound); an IPSS score of ≥12; and a Qmax in the range of 5 to 15 mL/sec in a total voided volume of ≥150 mL, were eligible for the study.

Exclusion criteria include but not limited to:

* Previous prostate surgery, presence of a prostate stent or microwave thermotherapy and/or balloon dilatation within the previous 6 months
* Concomitant therapy or previous therapy within 14 days with agents known to affect bladder or urethral function.
Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid

Considering the importance assumed by follicular microenvironment for a proper oocyte development, this study is a prospective observational clinical trial which aims to evaluate whether the embryo blastocyst quality may be affected by different Myo-inositol (MI) and D-chiro-inositol (DCI) levels in the follicular fluid (FF) of the aspired oocytes. The study includes egg donors and egg receiving couples participating in the oocyte donation program. MI/DCI is calculated in FF and related with blastocyst grade.


Eligibility Criteria:
Inclusion Criteria:

* clear follicular aspirate obtained during oocyte retrieval;
* each specimen of follicular fluid containing only one oocyte.

Exclusion Criteria:

* hyperglycaemic women;
* PCOS women also if euglycaemic;
* diabetic subjects having low concentrations of detectable MI in association with an anomalous MI transport.
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic response (the effect of the investigated drug on the body) of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
* Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for at least 12 months
* Body mass index (BMI) 18.0-28.0 kg/m\^2 (both inclusive)
* Glycosylated haemoglobin (HbA1c) maximum 9.5 %
* Fasting C-peptide maximum 0.3 nmol/L

Exclusion Criteria:

* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
* Not able or willing to refrain from smoking, use of nicotine gum or transdermal nicotine patches during the inpatient period
* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
* Surgery or trauma with significant blood loss (more than 500 mL) within the last 3 months prior to screening
Internal Carotid Artery Blood Flow in Infants With Prone Position

Little is known about how implementation of prone position contributes to general anesthesia-induced decrease in cerebral blood flow in infants. The investigators investigated this question in participants undergoing untethering, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.


Eligibility Criteria:
Inclusion Criteria:

* pediatric neurosurgical patients receiving surgery under prone position

Exclusion Criteria:

* patients diagnosed as hydrocephalus
* premature closure of fontanelle
* patients diagnosed as patent ductus arteriosus or other congenital heart disease.